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Abstract
Background: With increased availability of antibiotics and antifungal agents hepatitis B virus (HBV)
and hepatitis C virus (HCV) infections are becoming a cause for significant concern in HIV infected
children. We determined the seroprevalence and risk factors for HBV and HCV among HIV
infected children aged 18 months to 17 years, attending the Paediatric HIV Care and Treatment
Center (CTC) at Muhimbili National Hospital (MNH) in Dar-es-Salaam, Tanzania.
Methods: Investigations included; interviews, physical examination and serology for HBsAg, IgG
antibodies to HCV and alanine aminotransferase (ALT) levels. HIV serostatus and CD4 counts
were obtained from patient records.
Results: 167 HIV infected children, 88(52.7%) males and 79(47.3%) females were enrolled. The
overall prevalence of hepatitis co-infection was 15%, with the seroprevalence of HBV and HCV
being 1.2% and 13.8%, respectively. Hepatitis virus co-infection was not associated with any of the
investigated risk factors and there was no association between HBV and HCV. Elevated ALT was
associated with hepatitis viral co-infection but not with ART usage or immune status.
Conclusion: The high seroprevalence (15%) of hepatitis co-infection in HIV infected children
attending the Paediatrics HIV CTC at the MNH calls for routine screening of hepatitis viral co-
infection and modification in the management of HIV infected children.
Background
With more than 1.4 million women estimated to give
birth annually and 8.2% HIV prevalence rate at antenatal
clinics (ANC), approximately 122,000 HIV-infected
women deliver annually in Tanzania. Assuming a 40%
transmission rate in the absence of any intervention, an
estimated 48,000 children will become HIV-infected each
year. In 2003, the number of children (0–15 years) living
with HIV/AIDS in Tanzania was estimated to be between
85,000 and 230,000[1,2]. A large number of infected chil-
dren have been associated with significant increase in
morbidity, hospitalization and mortality [2].
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With increased access to antibiotics and antifungal agents
hepatitis viruses, especially hepatitis B and C, are emerg-
ing as the leading causes of morbidity and mortality
among children on ART [3].
Relatively little is known regarding HCV or HBV co-infec-
tion in HIV infected children in Tanzania. Thus, not sur-
prisingly the current national guidelines for management
of HIV disease in children do not include screening and
management of hepatitis viral co-infection.
We conducted this study to determine the seroprevalence
and risk factors for HBV and HCV among HIV infected
children aged 18 months to 17 years attending the paedi-
atric HIV Care and Treatment Center (CTC) at MNH, Dar-
es-Salaam, Tanzania.
Methods
Study design, setting and population
This cross sectional study was conducted at the Paediatrics
HIV CTC in Muhimbili National Hospital (MNH)
between April 2006 and August 2006. The MNH is the
largest referral and consultant hospital in Tanzania. All
HIV infected children who were attending the Paediatrics
HIV CTC at MNH during the study period were eligible.
Children included in this study were aged between 18
months and 17 years.
Interviews
Parents/guardians were interviewed using a standard
structure questionnaire to obtain information regarding
demographics, age, sex, and duration of illness, past med-
ical history such as history of blood transfusion, and
parenteral treatment, family and social history. Patient
record files were used to obtain information regarding
HIV status and CD4 count. Only recent CD4 values
(within three months) were recorded. Children were clas-
sified immunologically according to the immunological
classification for HIV-infected infants and children by
United States Centers for Disease Control and prevention
[4].
Physical examination
A thorough physical examination was done according to
standard clinical methods [5]. General examination, fol-
lowed by systemic examination was done. General exam-
ination included looking at the skin and mucous
membranes for the presence of jaundice especially the
sclera and mucous under the tongue, palmar pallor,
lymph node enlargement by palpation. Abdominal exam-
ination to elicit enlargement of the liver and spleen was
done.
Laboratory investigations
Detection of HBsAg and IgG antibody against hepatitis C virus
Detection of HBsAg was done using ELISA technique
(EIAgen HBsAg Kit). IgG antibodies to HCV were detected
using an ELISA technique (EIAgen HCV Ab Kit). The tests
which were done according to instructions of the manu-
facturer (adaltis Italia S.p.A) have specificity and sensitiv-
ity of 99% and 100% respectively.
Alanine aminotransferase (ALT) assay
Catalytic activity of ALT (EC 2.6.1.2) was determined in
serum using a COBAS MIRA chemistry analyzer (GMI, MI,
USA) after it was calibrated.
Statistical analysis
Data were entered, cleaned, and analyzed using EPI INFO
version 3.3.2 and SPSS version 10.0 [6]. The seropreva-
lence of HCV and HBsAg were expressed in percentages
for the entire study group and by age and sex. Chi-Square
(χ2) was used to determine the association between level
of immunosuppression with HBV and HCV. Fisher's exact
test was used where the expected frequency was less than
five. Univariate and multivariate regression were used to
determine the associations between elevation of ALT,
immunosuppression, ART and hepatitis co-infection. The
associations were presented as odds ratio (OR) together
with 95% confidence intervals (C1) and were considered
to be significant if the corresponding 95% C1 does not
include one.
Ethical issues
An oral informed consent was obtained from the parent/
guardian prior to enrollment and assent to those children
more than 10 years was also obtained. The following
information was given during parent/guardian education
to ensure that they have the information needed to make
an informed choice; a complete description of the aims of
the study, infectious agents that were screened, potential
benefits and risks, blood collection procedures and assur-
ance of confidentiality of any information given as well as
test results. Study personnel provided any other requested
additional information to parent/guardian. Children with
hepatitis co-infection were followed up at the clinic and
cared and managed accordingly.
Results
A total of 167 children were recruited between April and
august 2005. Among them, 88(52.7%) were males and
79(47.3%) were females. Most of the children (49.7%)
were aged 6–10 years. The overall prevalence of hepatitis
viral co-infection among the HIV infected children was
about 15% (25/167). The prevalence of hepatitis viral co-
infection was significantly higher among girls (21.5%)
than boys (9.0%). There was no association between age
and hepatitis viral co-infection. Two children (1.2%) wereBMC Public Health 2007, 7:338 http://www.biomedcentral.com/1471-2458/7/338
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co-infected with HBsAg and 23(13.8%) were co-infected
with HCV (Table 1). The prevalence of HCV was signifi-
cantly higher among girls (20.3%) than boys (8%) (P =
0.02) (Table 1). However there were no sex differences in
the occurrence of HBsAg P = 0.93 (Table 1). The occur-
rence of HCV was highest (28.5%) in children aged less
than two years and in children older than 10 years (Table
1). The same table shows that HBsAg were only seen in
two children aged 6–10 years. However the age differences
were not statistically significant, with P-values for HBsAg
and HCV being 0.72 and 0.69, respectively (Table 1).
There were 148 (88.6%) children with history of injec-
tion, 26 (15.6%) had blood transfusion, 48 (28.7%) had
uvulectomy and 2 (1.2%) were sexually abused. Among
those with history of injection 1(0.7%) had HBsAg co-
infection and 19(12.8%) had HCV. However, there was
no association between these risk factors and the occur-
rence of hepatitis viral co-infection (Table 2).
Among 167 HIV infected children 59 (35.3%) had no evi-
dence of immunosuppression, 59 (35.3%) had moderate
immunosuppression and 49 (29.3%) had severe immu-
nosuppression. There was no statistically significant asso-
ciation between immune status and hepatitis viral co-
infection.
None of the investigated children had HBV and HCV dual
infection.
Among 167 children, 15 (9%) had elevated ALT. The prev-
alence of elevated ALT among children co-infected with
hepatitis B or C virus was 20.0% as compared with 7.0%
among those without viral co-infection. Using logistic
regression analysis, children co-infected with hepatitis
Table 1: Seroprevalence of HBsAg and HCV infection by age and sex among HIV infected children
Sex Total sample HBsAg seropositive N (%) HCV seropositive N (%)
Male 88 1(1.1) 7(8.0)
Female 79 1(1.3) 16(20.3)
P = 0.93 P = 0.02
Age group (yrs)
<2 7 0 (0) 2 (28.5)
2–5 37 0 (0) 4 (10.8)
6–10 83 2 (2.4) 10 (12.0)
11–15 34 0 (0) 6 (17.6)
>15 6 0 (0) 1 (16.7)
P = 0.72 P = 0.69
Total 167 2 (1.2) 23 (13.8)
Table 2: Association between risk factors and HBsAg and HCV co-infection in HIV infected children.
Risk factor Total sample HBsAg N (%) HCV N (%)
Injection
Yes 148 1(7) 19(12.8)
No 19 1(5.3) 4(21.1)
*P = 0.21 *P = 0.30
Blood transfusion
Yes 26 0(0) 5(19.2)
No 141 2(1.4) 18(12.8)
*P = 1.00 P = 0.36
Uvulectomy
Yes 48 1 (2.1) 9 (18.8)
No 119 1 (0.8) 14 (11.8)
*P = 0.49 P = 0.32
Sexual abuse
Yes 2 0 (0) 0 (0)
No 165 2 (1.2) 23 (13.8)
*P = 1.00 *P = 1.00BMC Public Health 2007, 7:338 http://www.biomedcentral.com/1471-2458/7/338
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had 4 times more risk of elevated ALT than those without
hepatitis (OR 3.99, 95% CI 1.1–14.2 (Table 3).
One hundred and twenty five (74.9%) children were on
ART and among them 12(9.6%) had elevated ALT com-
pared with 7.1% among those who were not on ART
(Table 3). However, there was no statistically significant
association between elevated ALT and being on ART (P =
0.94) (Table 3).
Discussion
This study showed a high prevalence (15%) of hepatitis
co-infection, which is approximately one out seven HIV-
infected children. The prevalence of HCV alone observed
in this study was 13.8%, which is significantly higher than
7.1%, which was reported by Kitundu et al (Jesse Kitundu
– Post-transfusion hepatitis C seroprevalence in Tanza-
nian children. 2001) [7] in post-transfused Tanzanian
children. The difference between these studies could be
due the nature of the studied populations. In the present
study, all children were HIV infected and were therefore
more prone to hepatitis viruses, which share modes of
transmission. Secondly, the methods used were different,
in this study antibodies to HCV was detected using an
ELISA technique while in this study agglutination test was
used which is relatively less sensitive and less specific due
to potential cross reactions [8]. However, it is important
that these ELISA based results are confirmed with more
sensitive technique such as HCV-RNA by PCR, since it has
been shown that some positive ELISA results becomes
negative when confirmed by PCR [9].
The seroprevalence of HBsAg alone in this study was
1.2%, which is significantly lower than 12% observed by
Kitundu et al (Prevalence of Hepatitis B and C among chil-
dren transfused with anti-HIV negative donor blood at the
same hospital [unpublished observation]. A similar study
conducted in Kenya by Rana et al [10] found a prevalence
of hepatitis B to be 4%, among African children infected
with HIV.
In this study the prevalence of HCV/HBV was not associ-
ated with age (18 months to 17 years). One limitation of
this study was that children below 18 months were not
investigated due to methodological limitations associated
with the use of IgG based ELISA[9]. This limitation may,
at least in part, have obscured age trends.
Regarding HCV, females were more affected 17(21.5%)
than males 8(9%) a finding that is consistent with a study
done by Kitundu et al (Prevalence of Hepatitis B and C
among children transfused with anti-HIV negative donor
blood at MNH hospital in 2000) [unpublished data] in
the same setting but the reason for the differences in sex is
unclear.
In this study, 148 (88.6%) children had history of injec-
tion, 26 (15.6%) had Blood transfusion, 48 (28.7%) had
uvulectomy and 2 (1.2%) were sexually abused. However
none of these potential risk factors was associated with
occurrence of the hepatitis viruses, which in another study
conducted in the same hospital by Kitundu et al (Preva-
lence of Hepatitis B and C among children transfused with
Table 3: Association between elevated ALT, immune status, ART usage and hepatitis viral co-infection expressed as odds ratios with 
95% confidence intervals
Univeriate Multivariate
High ALT N(%) OR 95% CI OR 95% CI
Immunosuppressio
n
No evidence 1.0 - 1.0
Moderate 0.74 0.16–3.45(P = 0.69) 0.61 0.12–2.96(P = 0.54)
Severe 2.68 0.79–9.52(P = 0.13) 2.48 0.68–9.02(P = 0.94)
ART
Not on ART 3(7.1) 1.0 - 1.0
On ART 12(9.6) 1.38 0.37–5.15(P = 0.09 1.95 0.24–3.77(P = 0.94)
HBsAg
No 14(93.3) 1.0 -
Yes 1(6.7) 10.79 0.74–8.81(p = 0.14)
HCV
No 11(73.3) 1.0 - 0.1
Yes 4(26.7) 2.55 1.02–10.65(P = 0.04) 2.83 0.75–10.62(P0.12)
Hepatitis B/C viral 
co-infection
No 0(0.0) 1.0 1.0
Yes 5(20.0) 3.25 3.99 1.12–14.19(P = 0.03)BMC Public Health 2007, 7:338 http://www.biomedcentral.com/1471-2458/7/338
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anti-HIV negative donor blood at MNH hospital [unpub-
lished data]. This finding coupled with the young age of
infection, may indicate that possibly these children
acquired these viral infections vertically rather than hori-
zontally.
We found no association between HBV and HCV, a find-
ing that is in keeping with observations by Matee et al [8]
and Wadell et al [11] among blood donors in the same
hospital. Collectively these studies indicate that the epide-
miology of these viruses is different in our setting [8].
The higher prevalence of raised ALT (20.0%) was among
children co-infected with hepatitis virus compared with
7.0% without hepatitis co-infection (OR 3.99, 95% CI
1.12–14.19) (Table 3) is expected since hepatitis viruses
are known to elevate liver enzyme [12].
We found no association between ART and elevated ALT,
which is contrary to the findings of other studies [13-15].
Children recruited in this study were on first line regimen,
which does not contain protease inhibitors, which are
associated with more risk of elevated ALT than other
antiretrovirals [15]. There has also been reports that differ-
ent genotype of hepatitis C virus differ in their ability to
cause hepatotoxicity, with genotype 3 being more hepato-
toxic than genotypes 1, 2, and 4. It would be interesting to
perform genotyping of the HCV strains to better under-
stand the association with liver pathology.
The high prevalence of hepatitis co-infection among HIV
infected children indicates the need to revisit the current
guidelines for the clinical management of HIV and AIDS.
The regimen (zidovudine, lamivudine, and nevirapine for
children < 3 years, with efaviranz replacing nevirapine for
children > 3 years and didanosine, abacavir and ritonavir
boosted lopinavir as second line) does not take care of the
hepatitis co-infection. Although lamivudine works for
both HBV and HIV, prolonged lamivudine therapy can
result in drug-resistant HBV mutants and has been associ-
ated with hepatitis flares [16,17].
Conclusion
There is high seroprevalence (15%) of hepatitis viral co-
infection among HIV infected children attending the Pea-
diatrics HIV CTC at MNH. Furthermore the current man-
agement of paediatrics HIV cases at MNH need to address
issues related with hepatitis co-infection.
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